Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients

Belatacept is an intravenously infused selective T cell costimulation blocker approved for preventing organ rejection in renal transplant recipients aged ≥18 years. This phase I trial examined the pharmacokinetics and pharmacodynamics (percentage CD86 receptor occupancy [%CD86RO]) of a single dose o...

Descripción completa

Detalles Bibliográficos
Autores principales: Moudgil, Asha, Dharnidharka, Vikas R., Feig, Daniel I., Warshaw, Barry L., Perera, Vidya, Murthy, Bindu, Roberts, Mustimbo E., Polinsky, Martin S., Ettenger, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590112/
https://www.ncbi.nlm.nih.gov/pubmed/30582294
http://dx.doi.org/10.1111/ajt.15236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590112/
https://www.ncbi.nlm.nih.gov/pubmed/30582294
http://dx.doi.org/10.1111/ajt.15236

Ejemplares similares